Table 2.
Summary of VTE and Major Bleeding Rates in Trials Comparing Extended-Duration Thromboprophylaxis Strategies in Cancer Patients
| Ref. | Cancer | Patients, N | Drug | VTE Detection | VTE, % | Bleeding*, % |
|---|---|---|---|---|---|---|
| [48] | Gastrointestinal, genitourinary, gynecological | 167 | Enoxaparin 40 mg SC 6--10 days plus placebo 19--21 days | Symptomatic and asymptomatic VTE: DVT - venography; PE - VPS, pulmonary angiography | 12 | 3.6 (minor) 3.6 (major) |
| 165 | Enoxaparin 40 mg SC 25--31 days | 4.8 | 4.7 (minor) 5.1 (major) |
|||
| [49] | Abdominal (all patients)† | 178 | Dalteparin 5,000 IU OD plus GCS for 7 days | Symptomatic and asymptomatic VTE: DVT - venography; PE - VPS, spiral computerized tomography, autopsy | 16.3 | 0.9 (minor) 1.8 (major) |
| 165 | Dalteparin 5,000 IU SC OD plus GCS for 7 days, plus further 21 days | 7.3 | 1.5 (minor) 0.5 (major) |
|||
| [50] | Abdominal cancer sub-group | 198 total | Dalteparin 5,000 IU OD plus GCS for 7 days | 19.6 proximal DVT: 10.4 |
Not reported | |
| Dalteparin 5,000 IU SC OD plus GCS for 7 days, plus further 21 days | 8.8 proximal DVT: 2.2 |
|||||
DVT, deep vein thrombosis; GCS, graduated compression stockings; OD, once daily; PE, pulmonary embolism; SC, subcutaneous; VPS; ventilation perfusion scan; VTE, venous thromboembolism.
* For definitions of major bleeding see original studies.
†Included non-cancer patients